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Introduction: Pathologic complete response (pCR) to neoadjuvant
chemotherapy is associated with improved survival in solid tumors.
Southwest Oncology Group 9900 demonstrated a 9% pCR after
three cycles of paclitaxel/carboplatin every 21 days. We evaluated
pCR rate with intensive weekly paclitaxel in a phase II study.
Methods: Patients with non-small cell lung cancer, stage IB to IIIA,
were eligible and received carboplatin, area under the curve  6,
every 21 days 3 and paclitaxel 80 mg/m2 weekly 9. Primary
outcome was the pCR rate.
Results: Twenty patients with clinical stage IB (n  16), IIA (n 
1), IIB (n  1), and IIIA (n  2) were enrolled. Mean age was 65
years. Toxicity included grade 4 neutropenia in 1 (5%), grade 3
neutropenia in 3 (15%), grade 3 neuropathy in 1 (5%), and grade 3
nausea in 1 (5%). After neoadjuvant therapy, one patient refused
surgery and one died of a nontreatment-related event. Eighteen
patients underwent complete resection, 15 by lobectomy, and 3 by
pneumonectomy. Pathology revealed 3 (17%) patients with pCR.
The median follow-up is 67 months. For clinical stage IB (n  16),
the median overall survival has not been reached, and the 5-year
overall survival is 69%. All patients with pCR (n  3) remain alive
and disease-free. Improved overall survival was seen in patients who
were pathologically down-staged versus patients who were not, p 
0.05.
Conclusions: Neoadjuvant chemotherapy with intensive weekly
paclitaxel and carboplatin is well tolerated and does not increase
surgical morbidity. This intense regimen achieves rates of pCR and
survival that compares favorably with other reported induction
regimens and merits further investigation.
Key Words: Adjuvant/neoadjuvant therapy, Lung cancer clinical
trials, Lung cancer surgery.
(J Thorac Oncol. 2011;6: 1432–1434)
Lung cancer is the leading cause of cancer-related death inNorth America.1 Despite curative resection for early
stages I and II, 5-year survival ranges from only 39 to 67%.2
Recurrence most commonly occurs at distant sites, empha-
sizing the need for systemic therapeutic approaches to im-
prove cure rates.
Chemotherapy after surgical resection for lung cancer
has been shown to be beneficial in randomized trials.3,4
However, chemotherapy compliance in the postoperative set-
ting continues to be poor.5 Chemotherapy delivered before
surgery has been shown to have good compliance and with
the promising data of paclitaxel used in a weekly regimen, the
Brown University Oncology Group sought to evaluate the
preoperative delivery of weekly paclitaxel in combination
with carboplatin for early-stage non-small cell lung cancer in
a phase II trial.
MATERIALS AND METHODS
Inclusion criteria for the Brown University Oncology
Group phase II trial included biopsy proven non-small cell
lung cancer, age 18 years or older, clinical stage IB to IIIA
(minimal or nonbulky N2 disease), and postoperative pre-
dicted forced expiratory volume in 1 second 40%. Eligible
patients underwent imaging with computerized tomography
scan, magnetic resonant imaging of the brain, and positron
emission tomography scan. All patients underwent routine
cervical mediastinoscopy.
Neoadjuvant chemotherapy consisted of paclitaxel 80
mg/m2 given every week 9 and carboplatin, AUC  6,
given every 3 weeks 3. Computerized tomography scan
was performed after chemotherapy to measure clinical re-
sponse. Surgery was performed 2 to 6 weeks after chemo-
therapy. At surgery, the minimum extent of resection was
lobectomy along with mediastinal lymph node dissection.
Staging was according to American Joint Committee on
Cancer Staging 6th edition.2 Chemotherapy toxicity was
graded based on the National Cancer Institute Common
Toxicity Criteria for Adverse Events v3.0.6 Clinical response
was assessed using the Response Evaluation Criteria in Solid
Tumors guidelines.7 The primary outcome of this trial was
the rate of pathologic complete response (pCR). Due to the
importance of pCR in our trial, the entire primary tumor and
all mediastinal nodes were submitted for pathologic analysis
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with pCR defined as complete necrosis of the tumor cells or
the absence of any tumor cells. All pathology was reviewed
by our thoracic study pathologist (B.A.). Survival was esti-
mated by Kaplan-Meier method and compared using log-rank
test. Our institutional review board approved of this prospec-
tive phase II trial, and written informed consent was obtained
from all patients.
RESULTS
From 2004 to 2007, 20 patients were enrolled. Patient
characteristics are given in Table 1. All 20 patients complete
the prescribed three cycles of carboplatin and 16 of 20
patients received all 9 weeks of paclitaxel (four patients
missed 1 week of paclitaxel). Toxicity of chemotherapy
included grade 4 neutropenia in 1 (5%), grade 3 neutropenia
in 3 (15%), grade 3 neuropathy in 1 (15%), and grade 3
nausea in 1 (5%). After chemotherapy, radiographic complete
response was seen in 1 patient (5%), partial response in 7
(35%), stable disease in 12 (60%), and no patient had disease
progression.
After chemotherapy, one patient refused surgery and
received chemoradiation and one patient died of an unexpect-
edly nontreatment-related accidental event. These two pa-
tients not undergoing surgery both had clinical stage IIIA
(T2N2). The 18 (90%) patients who underwent surgery all
achieved complete resection as defined by the margin and the
highest mediastinal node being free of tumor involvement. Of
the 18 patient who underwent resection, pathology revealed 3
(17%) with pCR, one from each clinical stage of T2N0,
T1N1, and T2N1 with each of these patients experiencing
radiographic stable disease (1.9 cm), partial response (1.2
cm), and complete response, respectively. Including the 3
patients with pCR, a total of 7 (39%) patients were patho-
logically down-staged.
The median follow-up is 67 months. Overall survival
for clinical stage IB, which represented the majority of our
patients (n 16), was 69% at 5 years with the median not yet
reached. Overall survival was better for those patients who
were down-staged (from clinical staging to pathologic stag-
ing) versus those who were not (100% versus 55% at 5 years,
p  0.05). The three patients with pCR also remain disease-
free after follow-up of 68, 67, and 35 months.
DISCUSSION
In the treatment of early-stage lung cancer, a significant
benefit for postoperative or adjuvant chemotherapy was seen
in the National Cancer Institute of Canada JBR103 random-
ized trial. With longer follow-up of median more than 9
years, the positive results of JBR10 was reconfirmed by Butts
et al.8 However, the compliance of chemotherapy after sur-
gery has been poor. The JBR105 showed only 50% compli-
ance with the planned four cycles of postoperative chemo-
therapy. More recently, the Neoadjuvant Adjuvant Taxol
Carboplatin Hope (NATCH)9 randomized trial showed sig-
nificantly better compliance with three cycles of chemother-
apy when given preoperatively versus postoperatively (90%
versus 61% respectively, p  0.001). The recent Southwest
Oncology Group (SWOG) 990010 randomized trial showed a
79% compliance rate with three cycles of preoperative che-
motherapy. Furthermore, the neoadjuvant NATCH,9 SWOG
9900,10 and MRCLU2211 trials have all shown no increase in
operative morbidity and mortality in the setting of induction
chemotherapy before surgery.
With data showing the advantages of preoperative che-
motherapy delivery in terms of chemotherapy compliance
without increasing surgical morbidity, we sought to deter-
mine whether the results of neoadjuvant therapy can be
improved with a weekly paclitaxel chemotherapy regimen
in a phase II trial. To our knowledge, there have been no
published clinical trials assessing the delivery of weekly
paclitaxel in the preoperative setting for early-stage lung
cancer.
The use of weekly paclitaxel has been evaluated in
patients with advanced-stage lung cancer. Trials by Belani et
al.12 and Socinski et al.13 randomized delivering paclitaxel
weekly versus every 3 weeks in combination with carboplatin
for patients in stage IIIB and IV. A higher response rate (p 
0.037) was seen with weekly paclitaxel in the trial by Belani
et al.,12 with both trials showing no difference in the time to
progression and the overall survival. However, less chemo-
therapy toxicity was suggested with weekly paclitaxel. A
lower incidence of neuropathy, neutropenia, myalgia/arthral-
gia, and alopecia was seen while there was a higher incidence
of anemia. Socinski et al.13 also showed better quality of life
and less taxane-related side effects with the weekly regimen.
The results of our trial compares favorably with other
published trials. Patients receiving our weekly preoperative
TABLE 1. Patient Characteristics (n  20)
Characteristic
Gender
Male 8 (40)
Female 12 (60)
Age (yr) 65 (47–76)
FEV1 (L) 2.13 (1.12–3.51)
% Predicted FEV1 89 (59–124)
% Predicted DLCO 86 (34–121)
Extent of resectiona
Lobectomy 14 (78)
Lobectomy en-bloc chest wall 1 (5)
Pneumonectomyb 3 (17)
Any complicationa,c 2 (11)
Postoperative mortality 0
Clinical stage
T2N0d 16 (80)
T1N1 1 (5)
T2N1 1 (5)
T2N2 2 (10)e
Values are given as N (%) or mean (range).
a Denominator n  18, patients undergoing surgical resection.
b All were right-sided.
c Both were self-limiting atrial fibrillation.
d Median tumor size of this group was 4.0 cm.
e These two patients did not undergo surgery, see text for details.
FEV1, forced expiratory volume in 1 sec; DLCO, diffusion capacity of lung for
carbon monoxide.
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regimen had good compliance, favorable toxicity profile, and
low surgical morbidity as compared with the standard regi-
men of paclitaxel every 3 weeks. The 40% radiographic
response rate (5% complete, 35% partial) seen in our trial is
similar to that seen in the NATCH,9 SWOG 9900,10 and
MRCLU2211 trials (53%, 41%, and 49% respectively). Our
pCR rate of 17% also compares favorably with the same three
trials mentioned above (10%, 9%, and 4%, respectively).
Overall, 5-year survival of 69% in our trial for clinical stage
IB also compares favorably with published data. The CALBG
96334 adjuvant trial for stage IB saw a 5-year overall survival
of 60% for the treatment group, keeping in mind that this
result was based on pathologic staging which incurs a sur-
vival advantage over clinical staging used in preoperative
trials like ours. The American Joint Committee on Cancer
Staging 6th edition staging of lung cancer by Mountain2
showed a 38% 5-year overall survival for clinical stage IB.
The current 7th edition staging system purposed by Gold-
straw et al.,14 which removed large tumors 5 cm from stage
IB, showed a 5-year overall survival of 43% for clinical IB.
Our study has several limitations. First, this is not a
randomized trial and comparison with other studies is for the
purpose of discussion and any conclusions from such com-
parison should be accepted with caution. Second, the number
of patients in our trial is small. With the publication of
randomized trials establishing benefit of adjuvant chemother-
apy in resected early-stage lung cancer, it became difficult to
accrue to our neoadjuvant trial. This explains the 3-year
period needed to accrue the 20 patients. Third, our conclusion
regarding improved survival in patients with pathologic
down-staging should also be taken with some caution. Al-
though all patients analyzed were clinical stage IB or II, the
two groups (down-staged versus not down-staged) may not
be comparable due to the inherent inaccuracies of clinical
staging. The diminished survival for patient who did not
achieve pathologic down-staging may merely be due to the
fact that they began at a higher stage (not detected clinically)
rather than from the lack of chemotherapy effect. Although
the same could be said regarding those who were down-
staged (i.e., these patients were always at a lower stage and
was inaccurately staged clinically), we are confident that
down-staging due to chemotherapy effect truly did occur as
these patients were all down-staged by either pCR or by
tumor size becoming 3 cm (i.e., T2 to T1). The possible
inaccuracy of clinical staging in neoadjuvant trials can lead to
inequality between patient groups, and only through a ran-
domized trial this can be corrected.
In conclusion, preoperative chemotherapy with weekly
paclitaxel in combination with carboplatin is well tolerated
and does not increase postoperative morbidity and mortality.
This regimen achieves pCR and survival rates that compares
favorably with every 3 weekly induction regimens and merit
further investigation.
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